The original new drugs of the Third Military Medical University were selected into "top ten scientific and technological progress of Chinese universities"

Recently, the 2015 "top ten scientific and technological progress of Chinese institutions of higher learning" organized and selected by the science and Technology Committee of the Ministry of education was announced in Beijing Professor Zou Quanming of the Third Military Medical University was selected for the project of "class 1.1 original new drug oral Recombinant Helicobacter pylori vaccine" The picture shows Professor Zou Quanming's research team On December 23, the reporter learned from the official website of the Ministry of education that the 2015 "top ten scientific and technological progress of Chinese universities" project selection was announced, and the oral Recombinant Helicobacter pylori vaccine, a class 1.1 original new drug of the Third Military Medical University, was selected, which is the world's first HP vaccine with completely independent intellectual property rights According to reports, Helicobacter pylori (HP) is the main pathogen of chronic gastritis, gastric and duodenal ulcer Who has determined HP as the level 1 risk factor of gastric cancer There are more than 100 million patients with gastric disease in China, and 200000 people die of gastric cancer every year Therefore, HP is very harmful HP vaccine is an effective way to control the spread of infection and prevent the occurrence of related gastrointestinal diseases, but it has not been successfully developed abroad Professor Zou Quanming's team of the Third Military Medical University has completed the phase I, II and III clinical trials with more than 5000 people participating in the HP vaccine The results show that: it is safe and effective, with a protection rate of 71.8%; it has successfully developed the world's first HP vaccine with completely independent intellectual property rights, and obtained the national class 1.1 new drug certificate The team invented the design principle of "HP intramolecular adjuvant mucosal vaccine" and the first personal intramolecular adjuvant with high safety and efficiency; designed and manufactured a new HP vaccine component; created a series of technologies for mucosal vaccine preparation and efficacy evaluation; and developed the first international quality standard for production and verification of HP vaccine The results of this study were published in the lancet in 2015, which is a top medical journal in the world, and received a positive review of the same period's topics, causing widespread concern and high praise from international peers CCTV, science and technology daily and other domestic mainstream media and websites have carried out key reports one after another The vaccine has won the second prize of national technology invention and the first prize of Chongqing technology invention It has 4 international invention patents and 12 national invention patent authorizations It has successfully transferred the enterprise and obtained the achievement transfer fee of 225 million yuan The enterprise has completed the construction and trial production of HP vaccine industrialization facilities, and is applying for production approval, which will soon be listed for the benefit of human health It is reported that the 2015 "top ten scientific and technological progress of Chinese institutions of higher learning" was selected by the science and Technology Committee of the Ministry of education Since 1998, the selection of "top ten scientific and technological progress of Chinese colleges and universities" has been held for 18 times This selection activity has played a positive role in improving the overall level of science and technology of colleges and universities, enhancing the scientific and technological innovation ability of colleges and universities, and has a greater social impact and won a higher reputation.